Dan Samorodnitsky

Insmed’s freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first full quarter of sales. Insmed set Wall Street abuzz with new sales figures for its newly-approved bronchiectasis drug Brinsupri that... See more

The Beltway-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for Hetlioz and promised to keep pushing for an approval. The FDA has rejected Vanda Pharmaceuticals’ Hetlioz for jet lag due to disagre... See more

The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity. Crinetics Pharmaceuti... See more

The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer. The U.S. federal government has ended its recommendations that all children receive vaccines against the flu an... See more

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo looks to win the market before rival Lilly can arrive with its own oral option for obesity. After winning the race to get an obesity pill approved just befor... See more